4-(2-chlorophenoxy)-benzene-1,2-diamine | 43156-08-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-(2-chlorophenoxy)-benzene-1,2-diamine
• 英文别名: 4-(2-Chlorophenoxy)benzene-1,2-diamine
• CAS: 43156-08-7
• 化学式: C₁₂H₁₁ClN₂O
• 分子量: 234.685
• InChiKey: OPCDOGXUXLZLQP-UHFFFAOYSA-N

物化性质

• 沸点：
  375.1±37.0 °C(Predicted)
• 密度：
  1.329±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  61.3
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-(2-chlorophenoxy)-benzene-1,2-diamine 以 乙醇 为溶剂， 反应 2.0h， 生成 1-(5-(2-chlorophenoxy)-1H-benzimidazol-2-yl)-3-methylurea
  参考文献：
  名称：

  New benzimidazole-2-urea derivates as tubulin inhibitors

  摘要：

  Emerging drug resistance and other drawbacks limit tubulin inhibitors' therapeutic applications and developing novel tubulin inhibitors still attracts intensive efforts. We describe the discovery and structure-activity relationship study of a series of benzimidazole-2-urea derivatives as novel β tubulin inhibitors. The representative compound 6o potently suppressed the proliferation of a panel of human cancer cells (NCI-H460, Colo205, K562, A431, HepG2, Hela, MDA-MB-435S) with IC50 values of 0.040, 0.050, 0.006, 0.026, 1.774, 0.452 and 0.052 μM, respectively. Compound 6o obviously inhibited NCI-H460 spindles formation and induced cell cycle arrest at G2/M phase at 0.10 μM. Computational study suggested that 6o interacts with β tubulin in a novel binding mode. Our results suggested that benzimidazole-2-urea derivatives might be promising tubulin inhibitors with novel binding mode for further development.

  DOI：

  10.1016/j.bmcl.2014.07.035
• 作为产物：
  描述：

  2-硝基-5-氯苯胺 在 sodium tetrahydroborate 、 tin(ll) chloride 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 8.0h， 生成 4-(2-chlorophenoxy)-benzene-1,2-diamine
  参考文献：
  名称：

  5-[（o-，m-和p -R）-苯氧基] -2-苯并咪唑氨基甲酸甲酯的合成及光谱性质

  摘要：

  描述了十一种新颖的5-[（o-，m-，p -R）-苯氧基-2-苯并咪唑氨基甲酸酯甲酯，其具有可能的药理活性作为驱虫药。ir，1 H-nmr，13 C-nmr和质谱证实了所有产物的结构。

  DOI：

  10.1002/jhet.5570340307

文献信息

• Synthesis and spectral properties of methyl 5-[(<i>o</i>-,<i>m</i>-, and<i>p</i>-R)-phenoxy]-2-benzimidazolecarbamate
  作者：Eduardo Cortés Cortés、Luis Angel Araluce Anaya

  DOI：10.1002/jhet.5570340307

  日期：1997.5

  The preparation of eleven novel methyl 5-[(o-, m-, p-R)-phenoxy-2-benzimidazolecarbamates with possible pharmacological activity as anthelmintics is described. The structure of all products was corroborated by ir, 1H-nmr, 13C-nmr and mass spectra.

  描述了十一种新颖的5-[（o-，m-，p -R）-苯氧基-2-苯并咪唑氨基甲酸酯甲酯，其具有可能的药理活性作为驱虫药。ir，1 H-nmr，13 C-nmr和质谱证实了所有产物的结构。
• 5-芳基酚-2烷基取代脲苯并咪唑类化合物及 其应用
  申请人：中国科学院广州生物医药与健康研究院

  公开号：CN104876878B

  公开（公告）日：2018-04-27

  本发明公开了一种5‑芳基酚‑2烷基取代脲苯并咪唑类化合物及其应用，所述化合物具有式（Ⅰ）结构。本发明涉及的5‑芳基酚‑2烷基取代脲苯并咪唑类化合物在体外能够显著抑制多种肿瘤细胞的增殖，对肿瘤细胞的微管形成与细胞周期G2/M期的阻滞呈现出剂量依赖性；同时为临床治疗肿瘤提供了新的药物选择。
• Synthesis and spectral properties of 2,3-dihydro-4-(<i>paramethylphenyl</i>)-7-[(<i>o, m-</i>, and<i>p</i>-substituted)phenoxy]-1<i>H</i>-1,5-benzodiazepine-2-thiones
  作者：Eduardo Corés Cortés、Mario Martínez Torres

  DOI：10.1002/jhet.5570340337

  日期：1997.5

  A series of twelve new 2,3-dihydro-4-(para-methylphenyl)-7-[(o-, m-, and p-substituted)phenoxy]-1H-1,5-benzodiazepine-2-thiones. which have potentially useful pharmacological properties, has been synthesized by condensing the 3,3-dimercapto-1-(p-methylphenyl)-2-propen-1-one with 3,4-diaminophenyl-R-phenyl ethers. The structure of all products was corroborated by ir; 1H-nmr; 13C-nmr and ms.

  一系列十二个新的2,3-二氢-4-（对甲基苯基）-7-[（邻，间和对取代的）苯氧基] -1 H -1,5-苯并二氮杂-2-硫酮。通过将3，3-二巯基-1-（对甲基苯基）-2-丙烯-1-酮与3，4-二氨基苯基-R-苯基醚缩合，合成了具有潜在有用药理性质的化合物。ir证实了所有产品的结构；1 H-核磁共振; 13 C-nmr和ms。
• Discovery of Picomolar ABL Kinase Inhibitors Equipotent for Wild Type and T315I Mutant via Structure-Based de Novo Design
  作者：Hwangseo Park、Seunghee Hong、Jinhee Kim、Sungwoo Hong

  DOI：10.1021/ja311756u

  日期：2013.6.5

  Although the constitutively activated break-point cluster region-Abelson (ABL) tyrosine kinase is known to cause chronic myelogenous leukemia (CML), the prevalence of drug-resistant ABL mutants has made it difficult to develop effective anti-CML drugs. With the aim to identify new lead compounds for anti-CML drugs, we carried out a structure-based de novo design using the scoring function improved by implementing an accurate solvation free energy term. This approach led to the identification of ABL inhibitors equipotent for the wild type and the most drug-resistant T315I mutant of ABL at the picomolar level. Decomposition analysis of the binding free energy showed that a decrease in the desolvation cost for binding in the ATP-binding site could be as important as the strengthening of enzyme-inhibitor interaction to enhance the potency of an ABL inhibitor with structural modifications. A similar energetic feature was also observed in free energy perturbation (FEP) calculations. Consistent with the previous experimental and computational studies, the hydrogen bond interactions with the backbone groups of Met318 proved to be the most significant binding forces to stabilize the inhibitors in the ATP-binding sites of the wild type and T315I mutant. The results of molecular dynamics simulations indicated that the dynamic stabilities of the hydrogen bonds between the inhibitors and Met318 should also be considered in designing the potent common inhibitors of the wild-type and T315I mutant of ABL.
• Discovery of New Benzothiazole-Based Inhibitors of Breakpoint Cluster Region-Abelson Kinase Including the T315I Mutant
  作者：Seunghee Hong、Jinhee Kim、Sun-Mi Yun、Hyunseung Lee、Yoonsu Park、Soon-Sun Hong、Sungwoo Hong

  DOI：10.1021/jm301891t

  日期：2013.5.9

  The existence of drug resistance caused by mutations in the break-point cluster region-Abelson tyrosine kinase (Bcr-Abl) kinase domain remains a clinical challenge due to limited effective treatment options for chronic myeloid leukemia (CML). Herein we report a novel series of benzothiazole-based inhibitors that are effective against wild-type and T315I mutant Bcr-Abl kinases. The original hit compound, nocodazole, was extensively modified through a structure-based drug design strategy, especially by varying the groups at the C2 and C6 positions of the scaffold. In addition, the introduction of water-solubilizing groups at the terminal ethyl group resulted in enhanced physicochemical properties and potency in cellular inhibition. Several compounds inhibited the kinase activity of both wild-type Bcr-Abl and the T315I mutant with IC50 values in the picomolar range and exhibited good antiproliferative effects on Ba/F3 cell lines transformed with either wild-type or T315I mutant Bcr-Abl.